Charles Schwab Investment Management Inc. Sells 247,868 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Charles Schwab Investment Management Inc. trimmed its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 15.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,367,345 shares of the company’s stock after selling 247,868 shares during the period. Charles Schwab Investment Management Inc. owned 1.59% of Pediatrix Medical Group worth $15,848,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MD. Aristeia Capital L.L.C. acquired a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at $687,000. Rubric Capital Management LP lifted its holdings in Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after acquiring an additional 7,241,400 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in Pediatrix Medical Group by 14.1% during the third quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock worth $5,953,000 after acquiring an additional 63,581 shares in the last quarter. ClariVest Asset Management LLC bought a new position in Pediatrix Medical Group during the second quarter worth about $1,721,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Pediatrix Medical Group by 4.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 87,369 shares of the company’s stock worth $877,000 after acquiring an additional 3,669 shares in the last quarter. 97.71% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the transaction, the director now owns 138,683 shares of the company’s stock, valued at $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by company insiders.

Pediatrix Medical Group Price Performance

NYSE:MD opened at $14.80 on Friday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The stock’s 50-day simple moving average is $13.73 and its 200 day simple moving average is $10.52. The company has a market cap of $1.27 billion, a P/E ratio of -4.84, a P/E/G ratio of 2.11 and a beta of 1.57. Pediatrix Medical Group, Inc. has a 52-week low of $6.62 and a 52-week high of $16.41.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. Pediatrix Medical Group’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.29 earnings per share. As a group, sell-side analysts forecast that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft lifted their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. StockNews.com lowered Pediatrix Medical Group from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Jefferies Financial Group boosted their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Mizuho boosted their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th. Finally, Truist Financial boosted their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $16.10.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.